Showing results (61-70 of 70) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 70 results.
BMC Neurology|April 16, 2020
A case report of thrombolysis resistance: thrombus ultrastructure in an ischemic stroke patientYe Li, Heying Wang, Lili Zhao, et al.
Life Sciences|September 8, 2016
Curcumin ameliorates alveolar epithelial injury in a rat model of chronic obstructive pulmonary diseaseMing Zhang, Yingying Xie, Rui Yan, et al.
Psychological Medicine|May 13, 2024
Shared and distinct electroencephalogram microstate abnormalities across schizophrenia, bipolar disorder, and depressionRui Xue, Xiaojing Li, Wei Deng, et al.
Investigational New Drugs|October 27, 2023
Pharmacokinetics, pharmacodynamics and efficacy of pemigatinib (a selective inhibitor of fibroblast growth factor receptor 1-3) monotherapy in Chinese patients with advanced solid tumors: a phase i clinical trialTing Deng, Le Zhang, Yehui Shi, et al.
Advanced Healthcare Materials|August 7, 2023
A Nature-Inspired Versatile Bio-AdhesiveMingxia Chen, Taijun Chen, Jiafan Bai, et al.
Water, Air, and Soil Pollution|April 4, 2015
Air Quality in Lanzhou, a Major Industrial City in China: Characteristics of Air Pollution and Review of Existing Evidence from Air Pollution and Health StudiesYaqun Zhang, Min Li, Mercedes A Bravo, et al.
Environmental Monitoring and Assessment|May 6, 2016
Metals compositions of indoor PM2.5, health risk assessment, and birth outcomes in Lanzhou, ChinaYaqun Zhang, Suzhen Cao, Xiaoying Xu, et al.
Journal of the American Academy of Dermatology|April 5, 2026
A Multicenter, Randomized, Double-blinded, Placebo-Controlled Phase III Trial to Evaluate Efficacy and Safety of Picankibart in Moderate-to-Severe Plaque PsoriasisYunlu Gao, Lanying Qin, Yumei Li, et al.
Annals of Surgery|July 5, 2022
Efficacy and Safety of PL-5 (Peceleganan) Spray for Wound Infections: A Phase IIb Randomized Clinical TrialYating Wei, Jun Wu, Yuxin Chen, et al.
The Lancet. Oncology|June 18, 2021
Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 studyZhenggang Ren, Jianming Xu, Yuxian Bai, et al.
Pageof 7